The future of blood-based biomarkers for Alzheimer's disease. - Wikidata - awgldk - TriplyDB

The future of blood-based biomarkers for Alzheimer's disease.

The future of blood-based biomarkers for Alzheimer's disease.

http://www.wikidata.org/entity/Q34026317

about

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges Revolutionizing Alzheimer's disease and clinical trials through biomarkers The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease Network-based biomarkers in Alzheimer's disease: review and future directions Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling.Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.Blood biomarkers for amyotrophic lateral sclerosis: myth or reality?Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia Plasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer's disease.A platelet protein biochip rapidly detects an Alzheimer's disease-specific phenotype Blood biomarkers for Alzheimer's disease.Novel plasma biomarker surrogating cerebral amyloid deposition.Bayesian graphical network analyses reveal complex biological interactions specific to Alzheimer's disease A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder.The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations Blood biomarker for Parkinson disease: peptoids.Cancer biomarker discovery using DNA aptamers.Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers.Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics.Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients.Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.Differential diagnosis of mild cognitive impairment and Alzheimer's disease using structural MRI cortical thickness, hippocampal shape, hippocampal texture, and volumetry Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease.Differential proteomics analysis of liver failure in peripheral blood mononuclear cells using isobaric tags for relative and absolute quantitation.Dynamic and temporal assessment of human dried blood spot MS/MSALL shotgun lipidomics analysis PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects.Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.Biomarkers in Sporadic and Familial Alzheimer's Disease.Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders.Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data.Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid.Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside.

P2860

Q24289435-08C2FEB5-E6F9-41CC-9868-56FEDBCA223C Q24289443-77606137-BB6D-4495-A635-4A4584AEA25E Q26744882-A2E72584-5D9A-45D5-B4FC-649462A344EB Q26781635-E5A17E5F-3EB8-475E-86DB-502F2FB08686 Q26784569-FFA74EAB-8A5B-4FC8-9977-C9442E0B3209 Q26853347-A5CA781E-68C0-4ABB-A3F3-F545097B2DFB Q27023864-F1748D26-638D-4206-B3AC-D355F75ECDA6 Q28087176-C765E3DF-C594-4A60-A723-179BC4800215 Q30235315-DAB00F25-7B30-4FEA-B41B-8993B75B21D6 Q30996727-9B12AF4E-24D9-4537-8537-1D0B020E0FCF Q33767845-E8C6668D-4555-4CE6-B665-23876C95C2E6 Q33801596-5DF53171-ADF2-4E50-ADE3-7A07B72C8215 Q33895177-DBB0F4EB-2931-4C65-B79B-E644ADE20C93 Q34363475-B1B46B93-9956-42B2-A982-E6F2C5FFCFA8 Q34624763-39E24F40-0AB0-47DB-898D-1116838AA6BC Q35074431-B38C65A4-3998-4C4E-98E9-9463766D3529 Q35843380-3881E0C5-7BCE-4BC0-AAD2-292BF92E4983 Q36043355-4F7619BC-676F-4621-94A3-D31CF8BCB8C7 Q36165011-063A7E04-4F4B-4841-8466-149558BB459D Q36182485-FF65B8BE-FF4B-4076-8CD2-59129F8A3C43 Q36430991-26E8CA42-22CD-4DB5-B10A-5258EF9AA313 Q36934163-E9673431-CDB3-4053-A4A2-5590447F63DE Q37342809-BC0E1496-5404-42AC-9850-52C8300DA382 Q37346081-B3C0DD93-8602-4D18-8CF4-941116083A35 Q37445069-7F64C5A4-26F2-4C8E-819F-24AA56F4231D Q37451440-99BB8DFF-4AB4-46CD-82C4-83F550F2EC09 Q37530397-522115C7-CB17-411F-A97D-0BB489566206 Q37587482-05AEC3AD-E8D3-4756-A702-832EF4413238 Q37615645-422B0686-C664-4AD3-B20E-A69CCACD3471 Q37701236-4E5913EE-FB16-4867-A765-7A90C69931C6 Q37713619-74820A58-3428-4040-AFDB-244BA470AA9C Q37718557-33571CA1-8D06-4FAD-BB65-B65B85E89E78 Q37725397-E44578C1-35DD-4E77-B5A8-F3A27745644E Q38344088-183567DD-2F8D-4FF9-9A25-9BFB487A4EFB Q38592041-98E2DABD-57D5-41F2-B1C9-38F9B65CEB0C Q38592069-C7BCE76A-DC0B-404B-A336-9F8E390B55B9 Q38629703-A6E1E2FA-E7F8-425D-A0BE-783A157AF0B0 Q38666998-C1A2866A-AB66-47A7-B42D-B3E2A3DE1A24 Q39181900-A220EBF1-BB2B-4C9C-A5A6-EDDA7131D60B Q39432592-7D96EB9F-D6EC-44ED-98E8-A42A8AAB3173

P2860

The future of blood-based biomarkers for Alzheimer's disease.

http://www.wikidata.org/entity/Q34026317

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The future of blood-based biomarkers for Alzheimer's disease.

@ast

The future of blood-based biomarkers for Alzheimer's disease.

@en

The future of blood-based biomarkers for Alzheimer's disease.

@nl

type

label

The future of blood-based biomarkers for Alzheimer's disease.

@ast

The future of blood-based biomarkers for Alzheimer's disease.

@en

The future of blood-based biomarkers for Alzheimer's disease.

@nl

prefLabel

The future of blood-based biomarkers for Alzheimer's disease.

@ast

The future of blood-based biomarkers for Alzheimer's disease.

@en

The future of blood-based biomarkers for Alzheimer's disease.

@nl

P1433

Q34026317-E00A7F04-41C6-44F8-B83F-16FFB941CD4B

P1476

Q34026317-E82F93E4-BA04-467F-8C56-3AFCB597E4E8

P2093

Q34026317-03D0E988-AA9F-45B5-9894-66915DAE933F

Q34026317-22021432-630C-4582-A521-A6AD68F94183

Q34026317-3741F2AB-5146-494A-A594-C7571E4296EA

Q34026317-3A51F8F9-A7BA-4912-A3BE-6144D2780B80

Q34026317-7D9DC5B4-3EEA-42BE-8604-8E751306AFCB

Q34026317-82485FF2-75EA-4EC3-996F-E208FA36AB5F

Q34026317-981B5F92-EC6B-4EF9-92C1-0CF5F549039A

Q34026317-AEABBA05-7628-4F1A-B114-FDB96F60BAFB

Q34026317-FD34A23A-63AD-4634-A504-3CF6754EF272

P2860

Q34026317-0070CDA2-A652-41CC-91CE-81E1C8E4641B

Q34026317-01F21A9A-DE88-40D0-92F9-903DFEBF90C1

Q34026317-02F364F3-FE85-4B3B-A9AC-8EEFDA50F015

Q34026317-03807768-467B-44BA-90EA-4B6787A13B56

Q34026317-03A0F2FE-AD56-4DAB-97A7-E5355D547498

Q34026317-0415D6F4-63FC-41CB-B868-EB4CDA48D5F1

Q34026317-0A3B5EDC-86C3-492D-A001-D69730876174

Q34026317-0D00D82D-94C0-47BF-8CFC-D6C304A7CD1D

Q34026317-11DF3FA6-4CB3-40E9-81FD-1D60E61E0784

Q34026317-122D6EF1-C2D6-4C21-9321-D6EA4C685D46

P304

Q34026317-3561C709-7D88-40F8-8A13-9CB7B67E077D

P31

Q34026317-180DACFB-3B22-4D8E-A733-3535992B5E1A

P356

Q34026317-2A2436CE-0C17-4C0B-84AE-3ABCCD563EF7

P433

Q34026317-C66F5AA7-1A21-4123-9EB6-DE8F2DF93A55

P478

Q34026317-B868E34F-4B17-4EE4-A20D-844357E08D3C

P50

Q34026317-28A3D7A2-CB62-41D6-B3FE-6203929AF07B

Q34026317-3E515BA7-E164-4D6B-98C8-ACD18C0CA8FB

Q34026317-43AB33AF-F5F0-407F-B413-FD823789FBCB

Q34026317-4A17408D-2F9D-4B82-BBA6-744D82C5B8BC

Q34026317-7DD1D74A-CAF4-43D8-849F-2B9F05FD8386

Q34026317-B72A161B-A14E-45BC-99E2-DB42BA700743

Q34026317-CA17BE51-0ADB-41F1-A062-9DA45681787B

Q34026317-EDBD37DF-6168-42A2-90CB-2C575FA0D024

P577

Q34026317-98856464-F3A7-4C55-B520-1960244310F2

P5875

Q34026317-C1C9FDFA-B13A-43BD-ADBA-544835AF5EF7

P698

Q34026317-49FE1896-4119-4B47-A6B7-FF5B7179120C

P921

Q34026317-7CAFD98E-F801-4E5C-92A1-2E285E633B97

Q34026317-B10E1852-C4A3-4EC5-BA21-D5337E15C7DE

P932

Q34026317-BBC5A57D-25EA-48BB-866B-C05E5E24813E

P356

J.JALZ.2013.01.013

P1433

Alzheimer's and Dementia

P1476

The future of blood-based biomarkers for Alzheimer's disease.

@en

P2093

Anders Lönneborg

http://www.w3.org/2001/XMLSchema#string

Andreas Jeromin

http://www.w3.org/2001/XMLSchema#string

Blood-Based Biomarker Interest Group

http://www.w3.org/2001/XMLSchema#string

Chantal Bazenet

http://www.w3.org/2001/XMLSchema#string

Holly Soares

http://www.w3.org/2001/XMLSchema#string

Kim Henriksen

http://www.w3.org/2001/XMLSchema#string

Morten A Karsdal

http://www.w3.org/2001/XMLSchema#string

Thomas J Montine

http://www.w3.org/2001/XMLSchema#string

Tony Wyss-Coray

http://www.w3.org/2001/XMLSchema#string

P2860

SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease

alpha-Synuclein and neuronal cell death

Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics

Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases

Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease

Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease

Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS

Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers

Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells

P304

115-131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JALZ.2013.01.013

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Simon Lovestone

Michael W. Weiner

Magnus Sjögren

John Q. Trojanowski

P577

2013-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259523181

http://www.w3.org/2001/XMLSchema#string

P698

23850333

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

4128378

http://www.w3.org/2001/XMLSchema#string